Through technology and science BGM Pharmaceuticals, UCT and NECSA have developed a new theranostics to deal with cancer. This partnership will be to bring about a one-of-a-kind cancer diagnosis and treatment innovation ... (Press release)
“The initial investment of R600m in the development of the theranostic will ensure that clinical trials prove safety and efficacy in a sufficient number of human subjects. More investment will be required to conduct multi-centre and multi-country clinical trials and in so doing, elevate GluCAB to global blockbuster status,” says BGM Pharma.